For decades, parents and physicians across Southeast Asia have watched helplessly as young children deteriorated rapidly from a disease that wore the mask of a common illness. Vietnam has now become the first country in the region to offer a dedicated vaccine against Enterovirus 71, the most dangerous strain of hand, foot and mouth disease, making Envacgen available to children as young as two months old through nearly 300 vaccination centers nationwide. With 96.8 percent efficacy demonstrated in trials and 31 deaths recorded in Vietnam in 2023 alone, the rollout marks a quiet but consequentia
Vietnam launches first EV71 vaccine for hand, foot and mouth disease
In 2023, Vietnam recorded 31 deaths from hand, foot and mouth disease, with EV71 accounting for 90.4% of severe cases; the disease can cause rapid deterioration requiring intensive care.
Children can shift from alert to critical within hours
Mark
So Vietnam is the first country in Southeast Asia to have this vaccine. What took so long?
Mimi
Scientists have been working on EV71 vaccines for decades, but the virus is tricky. It's not like measles or polio—there are multiple strains, and EV71 specifically was the hardest to crack. The Phase 3 trials here showed 96.8 percent efficacy, which is why they finally approved it.
Luke
That's a strong number. But I want to be clear—that's efficacy against EV71-associated disease specifically, not against all hand, foot and mouth disease. The source says EV71 caused 82 percent of hospitalizations in 2023, so there are other viruses causing the remaining cases that this vaccine doesn't cover.
Mark
Right. So it's not a complete solution.
Mimi
No, but it's addressing the most dangerous part. EV71 is what causes the severe cases—the ones where children deteriorate within hours, the ones that need intensive care. That's what doctors have been waiting for.
Luke
And Taiwan's been using it since 2023. Over 600,000 doses. That's real-world data now, not just trial data.
Mark
How many children in Vietnam actually got vaccinated on the first day?
Mimi
The VNVC system recorded tens of thousands of registrations across nearly 300 centers. About 70 percent were children under three.
Luke
That's registrations, though. We don't know how many actually completed the full course. And we don't know what the uptake will be over time—whether parents will keep bringing their kids back for the second or third dose.
Mark
Fair point. But the fact that doctors are relieved—that matters, doesn't it?
Mimi
Absolutely. These are pediatric infectious disease specialists saying they've been waiting years for this. When you have 181,000 cases in a year and 31 deaths, and you know some children can go from alert to critical in six hours, you understand why they're relieved.
Luke
The 31 deaths—that's real. And EV71 accounted for 90.4 percent of severe cases. So this vaccine, if uptake is good, could prevent a lot of suffering.
Mark
What happens next?
Mimi
The vaccine is available now. The question is whether families will use it, especially before the next peak season.
El Pulso
- EV71 can transform a child from alert to critical within six to eight hours, and its mild early symptoms often mask the neurological storm building beneath — making prevention far more powerful than treatment.
- Vietnam recorded over 181,000 hand, foot and mouth cases and 31 deaths in 2023, with EV71 driving 90.4% of severe cases and repeatedly overwhelming hospital wards during peak seasons.
- Envacgen's Phase 3 trials across more than 3,000 Vietnamese children produced a 96.8% efficacy rate with zero EV71 cases among vaccinated participants, offering the strongest clinical signal yet that the disease can be stopped before it starts.
- On launch day, tens of thousands of families registered across Hanoi, Ho Chi Minh City, Da Nang, and other cities — with children under three, historically the hardest hit, making up roughly 70% of those seeking vaccination.
- Taiwan's experience administering over 600,000 doses since August 2023 has provided real-world confirmation of the vaccine's safety, lending confidence to Vietnam's nationwide rollout ahead of peak disease season.
For decades, parents and physicians across Southeast Asia have watched helplessly as young children deteriorated rapidly from a disease that wore the mask of a common illness. Vietnam has now become the first country in the region to offer a dedicated vaccine against Enterovirus 71, the most dangerous strain of hand, foot and mouth disease, making Envacgen available to children as young as two months old through nearly 300 vaccination centers nationwide. With 96.8 percent efficacy demonstrated in trials and 31 deaths recorded in Vietnam in 2023 alone, the rollout marks a quiet but consequential shift — from reactive medicine to preventive protection for the region's most vulnerable.
Vietnam has launched Envacgen, the first vaccine against hand, foot and mouth disease caused by Enterovirus 71, making it the first country in Southeast Asia to deploy such protection. Available at nearly 300 VNVC vaccination centers, the vaccine is approved for children from two months to six years of age following Ministry of Health authorization in March.
Developed by Switzerland-based Substipharm Biologics in partnership with VNVC, Envacgen was tested in Phase 3 trials involving more than 3,000 Vietnamese children. It demonstrated 96.8 percent efficacy, with no EV71 cases recorded among vaccinated participants and strong immune responses across multiple viral sub-genotypes. The vaccine requires two or three doses depending on the child's age at first vaccination.
The urgency behind the rollout is stark. In 2023, Vietnam recorded more than 181,000 cases and 31 deaths from the disease. EV71 accounted for 90.4 percent of severe cases that year. The virus is especially treacherous because it can invade the central nervous system, and children may deteriorate from apparent mild illness to a critical state requiring intensive care within six to eight hours — sometimes with few visible skin symptoms to alert parents or clinicians.
Doctors who have spent years managing outbreaks greeted the vaccine with relief. Specialists at Children's Hospital 1 in Ho Chi Minh City described the speed of deterioration they routinely witness, while infectious disease physicians noted that parents have long asked when prevention would finally be possible. On launch day, families across major Vietnamese cities responded immediately — tens of thousands registered, with children under three accounting for roughly 70 percent of those seeking vaccination.
Taiwan has already administered more than 600,000 doses of Envacgen since August 2023, with ongoing post-vaccination monitoring affirming its safety and effectiveness. For Vietnam, the vaccine's arrival does not erase years of reactive outbreak management, but it opens, for the first time, the possibility of meeting this disease before it reaches a child's door.
Vietnam has begun rolling out a vaccine against hand, foot and mouth disease caused by Enterovirus 71, marking the first time such a vaccine has been introduced in the country and across Southeast Asia. The vaccine, called Envacgen, is now available at nearly 300 vaccination centers run by the VNVC Vaccination System, with the official launch occurring on Friday. Children as young as two months old are eligible, and the Ministry of Health approved the vaccine in March for use in children up to age six.
The development represents a significant milestone in disease prevention. Scientists have spent decades trying to create an effective vaccine against hand, foot and mouth disease, which is caused by multiple viruses. The particular challenge has been developing protection against EV71, the strain responsible for the most severe cases. Envacgen, developed by Switzerland-based Substipharm Biologics in partnership with VNVC, underwent Phase 3 clinical trials in Vietnam involving more than 3,000 children. The results showed a 96.8 percent efficacy rate against EV71-associated disease. Among vaccinated participants in the trial, no cases of EV71 were recorded. The vaccine also generated strong immune responses against multiple EV71 sub-genotypes and demonstrated a favorable safety profile in follow-up studies.
The timing of the rollout addresses an urgent public health need. In 2023, Vietnam recorded more than 181,000 cases of hand, foot and mouth disease and 31 deaths. EV71 accounted for 82 percent of hospitalized cases and 90.4 percent of severe cases that year. The virus is particularly dangerous because it can affect the central nervous system, leading to neurological, respiratory, and cardiovascular complications. Children can deteriorate rapidly—sometimes within six to eight hours—from what initially appears to be a mild illness to a critical state requiring intensive care. Some infected children show limited skin symptoms, making the disease harder to distinguish from common illnesses until serious complications emerge.
On the first day of the nationwide rollout, families across Hanoi, Ho Chi Minh City, Da Nang, Can Tho, and other cities brought their children for vaccination. The VNVC system recorded tens of thousands of registrations at its centers nationwide, with children under three years old accounting for approximately 70 percent of those seeking vaccination. This age group has historically borne the heaviest burden of the disease.
Doctors have long awaited this vaccine. Dr. Trương Hữu Khanh, Vice Chairman of the Ho Chi Minh City Association of Infectious Diseases and a pediatric infectious disease specialist, noted that parents have repeatedly asked him when protection would become available. During each disease season, hospitals face surging admissions and parents experience significant anxiety. When major outbreaks occur, the rapid influx of patients strains healthcare systems and depletes medical resources. Dr. Nguyen An Nghia, Deputy Head of the Department of Infectious Diseases and Neurology at Children's Hospital 1 in Ho Chi Minh City, emphasized the speed of deterioration—children can shift from appearing alert to requiring emergency intervention within hours.
The vaccine requires two or three doses depending on the child's age at the start of vaccination. The VNVC system has prepared supply chains, storage facilities, trained staff, and distributed doses to its centers ahead of the peak season for hand, foot and mouth disease. Taiwan has already used the vaccine, with more than 600,000 doses administered between August 2023 and September 2026. Post-vaccination monitoring there has continued to confirm the vaccine's safety and effectiveness, according to Professor Dr. Li-Min Huang, former Director of the National Taiwan University Children's Hospital.
The introduction of Envacgen represents a shift in how Vietnam can manage a disease that has caused repeated waves of severe illness among its youngest children. For years, the medical response has been reactive—managing outbreaks as they occur, treating complications, and hoping for recovery. Now, for the first time, families have the option to prevent the disease before exposure. Whether widespread uptake will substantially reduce the burden of hand, foot and mouth disease in Vietnam remains to be seen, but the vaccine's arrival marks a turning point in pediatric infectious disease prevention in the region.
Citas Notables
Parents have asked me for years when a vaccine against hand, foot and mouth disease would become available. During each disease season, parents are worried and doctors are under pressure.— Dr. Trương Hữu Khanh, Vice Chairman of the Ho Chi Minh City Association of Infectious Diseases
Children with hand, foot and mouth disease can deteriorate from a mild condition to a critical state within six to eight hours.— Dr. Nguyen An Nghia, Deputy Head of the Department of Infectious Diseases and Neurology at Children's Hospital 1 in Ho Chi Minh City
Quieres la nota completa?
Lee el original en The Star ↗